



פיזר פי אף אי פרמצבטיקה ישראל בע"מ
רח' שנקר 9, ת.ד. 12133
הרצליה פיתוח, ישראל 46725
טל: 972-9-9700500 פקס: 972-9-9700501

מרץ 2020

רופא/ה, רוקח/ת נכבד/ה,
אנו מתכבדים להודיעך על תחילת שיווק של תכשיר חדש:

IXIFI 162-94-35522-00

אִיקְסִיפִי

התוויה מאושרת:

Adult Crohn's disease

IXIFI is indicated for treatment:

- of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
- treatment of fistulising, active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

Ulcerative colitis

• IXIFI is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Rheumatoid arthritis

IXIFI, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:

- adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate.
- adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X ray, has been demonstrated.

Ankylosing spondylitis

IXIFI is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.

Psoriatic arthritis

IXIFI is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

* IXIFI should be administered:

- in combination with methotrexate
- or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.

Infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease.

Psoriasis

IXIFI is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA)

חוזק:

INFLIXIMAB 100 MG

צורת מינון:

POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

גודל אריזה:

1 Vial per carton

יצרן:

PFIZER MANUFACTURING BELGIUM NV, BELGIUM
 RIJKSWEG 12, B-2870 PUURS, BELGIUM

משווק:

Pfizer PFE Pharmaceuticals Israel Ltd. 9 Shenkar St., Herzliya Pituach, 46725

העלונים נשלחו למשרד הבריאות לצורך פרסומם במאגר התרופות שבאתר משרד הבריאות:

<http://www.health.gov.il/units/pharmacy/trufot/index.asp>

לחילופין, לקבלת עלון מלא מודפס ניתן לפנות לחברת: פייזר פי אף אי פרמצבטיקה ישראל
 בע"מ

רח' שנקר 9, ת.ד. 12133, הרצליה פיתוח, 46725

בכבוד רב,
 אורטל עבודי
 רוקחת ממונה